SecBot SecBot
8-K ·Filed Jun 17, 2026

CORT

CORCEPT THERAPEUTICS INC
BULLISH
Impact 6/10
Horizonmonths Processed5mo ago SEC0001193125-26-274258
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

Monitor for FDA acceptance of the resubmission and subsequent PDUFA date assignment, expected within 30 days. If accepted, a decision by late 2026 would be the next major catalyst. The stock has a history of strong positive reactions to regulatory progress on relacorilant.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$79.91
T+0 close · Jun 17, 2026 · via day close
Latest settled
+39.91%
T+60 · $111.80
Vs SPY
+38.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 18 $79.91entry
  2. T+1 · 5mo ago −0.25%α +0.06% · $79.71
  3. T+5 · 5mo ago +6.06%α +7.72% · $84.75
  4. T+20 · 4mo ago +12.28%α +11.74% · $89.72
  5. T+60 · 2mo ago +39.91%α +38.01% · $111.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Corcept Therapeutics resubmitted its New Drug Application (NDA) to the FDA for relacorilant as a treatment for Cushing's syndrome, including additional analyses requested by the agency. The NDA is based on positive Phase III data from the GRACE and GRADIENT trials, and the company expects a six-month review. This represents a key step toward potential label expansion for a drug already approved in ovarian cancer, but approval is not guaranteed.

Key Facts

  • NDA for relacorilant (Cushing's syndrome) resubmitted to FDA on June 17, 2026.
  • Resubmission includes additional analyses of prior data as requested by the FDA.
  • Corcept expects a six-month review cycle (~6 months).
  • Positive data from pivotal GRACE trial, Phase III GRADIENT trial, and long-term extension study support the NDA.

Financial Impact

Not specified

pipeline advancementregulatory risk

Risk Factors

  • FDA may request additional clinical data or deny approval.
  • Competition from existing Cushing's therapies (e.g., Korlym, Isturisa) may limit market share.
  • Six-month review timeline could extend if FDA issues a complete response letter.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-274258
Document: d159941dex991.htm0001193125-26-274258
Document: 0001193125-26-274258-index-headers.html0001193125-26-274258
Document: 0001193125-26-274258-index.html0001193125-26-274258
Document: 0001193125-26-274258.txt0001193125-26-274258

Track record

36 reports on CORT

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +63.06% at T+60 after the Feb 24, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $73.87 Now $69.22 −6.29% settles Dec 15
  2. Nov 10, 20266d ago 144 Neutral 2/10 Entry $74.53 Now $69.22 −7.12% settles Dec 10
  3. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $71.63 Now $69.22 −3.36% settles Dec 4
  4. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $79.22 Now $69.22 −12.62% settles Dec 3
  5. Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $81.93 Now $69.22 +15.51% settles Dec 2
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $86.28 Now $69.22 −19.77% settles Nov 25
  7. Oct 5, 20266w ago Insider Cluster Neutral 3/10 Entry $119.57 to $81.93 Now $69.22 −42.11% ▼ −31.48% −28.30% vs SPY
  8. Sep 23, 20267w ago 8-K Neutral 3/10 Entry $112.94 to $116.28 Now $69.22 −38.71% ▲ +2.96% +2.27% vs SPY
  9. Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.50% vs SPY
  10. Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.75% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (10h 16m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 17, 2026